Home›Trial›NCT07001319
NCT07001319Phase 1RECRUITING

Study of GS-3242 in Participants With HIV-1; Substudy-05

Study Summary

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.

Conditions
HIV-1-infection
Interventions / Drugs
GS-3242BVYStandard of Care
View on ClinicalTrials.gov ↗
Sponsor
GILD
Gilead Sciences
Antiviral
F28/100
Study Details
Enrollment30 participants
Primary Completion—
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.112974+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 30 participants
Sponsor Catalyst Profile

Gilead Sciences (GILD) is the sponsoring company for this trial. BiotechSign currently grades this company F (28/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

GILD Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.